NPPA notified regarding the computation of the retail price of Empagliflozin 5 mg + Metformin Hydrochloride IP 1000 mg (in extended-release form) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Cipla Ltd. (Marketer)

Feb 21, 2025 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific ComplianceThe National Pharmaceutical Pricing Authority (NPPA) on February 20, 2025, was notified regarding the computation of the retail price of Empagliflozin 5 mg + Metformin Hydrochloride IP 1000 mg (in extended-release form) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Cipla Ltd. (Marketer).

It states that the price of each Film Coated Bilayered Tablet containing: Empagliflozin 5 mg + Metformin Hydrochloride IP 1000 mg (in extended-release form) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Cipla Ltd. (Marketer) has been revised to Rs. 11.83/-.

[Notification no: 19(4378)/2024/DP/NPPA/DIV.II]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT